Gilberto Gandra

VoxCell BioInnovation is advancing the future of in vitro modeling. We develop 3D bioprinted, vascularized human-like tissue models that closely replicate native biology, offering a powerful tool for more predictive, physiologically relevant research. Leveraging our proprietary high-resolution bioprinter, advanced vascularization software, and Universal Bioinks™, we produce complex tissue models that mirror patient biopsy samples in structure and function. Our flagship product is a 3D vascularized model of Triple Negative Breast Cancer (TNBC), designed to support applications in disease modeling, drug screening, vascular toxicity, and targeted delivery. Delivered as ready-to-use, perfusable models, VoxCell’s consumable products serve pharmaceutical companies, biotech firms, CROs, and academic researchers seeking to reduce translational gaps and accelerate biomedical innovation.

Venture Backed is breaking barriers and uniting the venture capital community. We put all of your resources in one place, so you can make wise investments with confidence. Plus, we create a pathway for founders to get their businesses off the ground! Our platform unlocks powerful tools that allow investors access to data-backed decisions - revolutionizing investing as we know it today. Venture Backed is a wholly owned subsidiary of VBCHC: https://vbchc.com

Omeat is a food startup that has pioneered a scalable way to produce cultivated meat that’s delicious, affordable, orders-of-magnitude more sustainable than conventional meat, and doesn’t involve sacrificing an animal. The secret to Omeat is a proprietary process that harnesses the intrinsically regenerative factors within cows plasma to foster cell growth. Omeat’s growth media is a cost-effective alternative to fetal bovine serum and can be used to cultivate any kind of meat. Omeat is based in Los Angeles, founded in 2020 by world-renown tissue biologist Dr. Ali Khademhosseini. The company is currently building a pilot plant and rapidly expanding its team toward commercial readiness.

Lunasonde makes the underground world visible, fundamentally transforming our understanding of the planet we live on. Through our revolutionary low-frequency radar, we’re pioneering subsurface imaging while providing a sustainable approach to resource exploration.

Rezilient Health is revolutionizing healthcare delivery through its innovative hybrid care model, combining advanced technology with remote physician expertise to deliver superior clinical outcomes. Through its network of CloudClinics, Rezilient provides accessible, high-quality healthcare while reducing overall healthcare costs for employers and patients.

Enabling users to establish #ownership & #control over their Biosamples & derived datasets as Non-fungible Tokens. We call them #BioNFTs 🧬.

Axion assists in building future Canadian technology power houses by helping inventors protect and scale their IP and navigate through the investment and funding landscape. Our mission is to accelerate Canada into an innovation economy by: i) Making angel investment accessible to investors who otherwise are unable to participate ii) Promoting the creation and commercialization of intellectual properties and hyper growth outcomes with an added focus on Northern Ontario iii) Removing barriers for Canadian inventors to connect to investors and industry partners Axion has two principal investment thesis: i) Axion Canadian IP Initiative (AIPI) AIPI is geared to assist in the commercialization and growth of ideas and research-based companies, generated within universities and other innovation centres across Canada. ii) Axion Northern Ontario Initiative (ANI) ANI is geared to attract, mentor, coach, fund and commercialize, early-stage start-ups and later-stage scale-ups that have a plan to partly or entirely be situated in, or desire to locate in some form to Northern Ontario. Axion is a part of the Archangel Network of Funds, an overarching angel stage investment fund with the mission of unlocking capital through the support of a consortium of super angels and venture capitalists.

Titanium Escrow is an independent escrow agent and paying agent regulated by the ADGM Financial Services Regulatory Authority under a Category 3C licence. Since 2020, we have held and released over USD 5 billion in client funds across M&A, restructuring, litigation settlement, and high-value real estate mandates, with a 100% on-time release rate. Client money is held in fully segregated accounts at Emirates NBD under Client Money Protection rules, with AED accounts grandfathered under Federal Decree-Law No. 6 of 2025. Because we are not a lender, an investor, or a counterparty to any transaction we administer, our release mechanics remain objective, technical, and governed solely by the escrow deed. CORE TRANSACTIONAL EXPERTISE • CORPORATE & M&A: Completion Accounts, Earn-outs, Retention Funds, and Deferred Consideration. • FUNDS & SECONDARIES: Capital Calls, Shareholder Distributions, and LP Interest Transfers. • SPECIAL SITUATIONS: Third-Party Custodian for Insolvency, Restructuring, and Distressed Debt. • LITIGATION: Settlement fund management for regional and international arbitration. • REAL ESTATE: High-value UAE escrow structures and Manager’s Cheque issuance. COUNSEL-INTEGRATED APPROACH We are instructed by and work directly alongside law firms across ADGM, DIFC, onshore UAE, and international jurisdictions, private equity sponsors, and family offices. KYC, AML, and settlement mechanics are handled on our side of the deed, allowing counsel to focus on the transaction rather than its administration. ADGM Reg. No. 000003948 | FSRA FSP No. 200010 www.titaniumescrow.ae

VoxCell BioInnovation is advancing the future of in vitro modeling. We develop 3D bioprinted, vascularized human-like tissue models that closely replicate native biology, offering a powerful tool for more predictive, physiologically relevant research. Leveraging our proprietary high-resolution bioprinter, advanced vascularization software, and Universal Bioinks™, we produce complex tissue models that mirror patient biopsy samples in structure and function. Our flagship product is a 3D vascularized model of Triple Negative Breast Cancer (TNBC), designed to support applications in disease modeling, drug screening, vascular toxicity, and targeted delivery. Delivered as ready-to-use, perfusable models, VoxCell’s consumable products serve pharmaceutical companies, biotech firms, CROs, and academic researchers seeking to reduce translational gaps and accelerate biomedical innovation.

Venture Backed is breaking barriers and uniting the venture capital community. We put all of your resources in one place, so you can make wise investments with confidence. Plus, we create a pathway for founders to get their businesses off the ground! Our platform unlocks powerful tools that allow investors access to data-backed decisions - revolutionizing investing as we know it today. Venture Backed is a wholly owned subsidiary of VBCHC: https://vbchc.com

Techstars helps founders scale their startups into world-changing businesses. Founded in 2006, Techstars is on a mission to invest in startups to enable more capital to flow to more entrepreneurs around the world in order to deliver exceptional returns to our investors. We do this by operating accelerator programs and venture capital funds, as well as by connecting startups, investors, corporations, and cities to help build thriving startup communities. Our results show why Techstars is Better for Founders than any other global accelerator: On average, 74.5% of Techstars companies will raise money within 3 years of their program; 18.5% of Techstars portfolio companies have exited 5 years after their program and 31.1% after eight years. (PitchBook June 2023)

We back remarkable teams in both *Social and Sustainable Tech* 💚